DiVincenzo Jonathan P.
Known title: President & COOCIK: 0001453524
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Labcorp to Acquire OPKO Health's BioReference Assets for $722M. Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.
Transaction History
| BIO | ▲ Buy | Option Exercise | 1,712 | $0 | 9/5/2026 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 668 | $258K | 9/5/2026 | View on chart |
| BIO | ▲ Buy | Option Exercise | 1,869 | $0 | 10/24/2025 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 950 | $323K | 10/24/2025 | View on chart |
| LH | ▼ Sell | Tax Withholding | 952 | $206K | 3/27/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 3,012 | — | 3/27/2024 | View on chart |
| LH | ▼ Sell | Open Market | 500 | $108K | 2/21/2024 | View on chart |
| LH | ▼ Sell | Tax Withholding | 59 | $13K | 2/12/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 201 | — | 2/11/2024 | View on chart |
| LH | ▼ Sell | Tax Withholding | 78 | $17K | 2/7/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 138 | — | 2/7/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 224 | — | 2/7/2024 | View on chart |
| LH | ▼ Sell | Tax Withholding | 41 | $9K | 2/7/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 246 | — | 2/2/2024 | View on chart |
| LH | ▼ Sell | Tax Withholding | 85 | $19K | 2/2/2024 | View on chart |
| LH | ▼ Sell | Tax Withholding | 19 | $4K | 12/15/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 64 | — | 12/15/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Bio‑Rad Leads in Recombinant Protein & Magnetic Bead Growth
The latest market report shows the recombinant protein manufacturing sector is expected to triple in revenue by 2030, with Bio‑Rad listed among the key players. A separate analysis projects the magnetic bead market to grow from $3.3 billion in 2025 to $7.4 billion by 2032, again naming Bio‑Rad as a leader. These developments highlight the company’s expanding role in both protein production and diagnostic reagent markets.
Bio‑Rad Leads in Recombinant Protein & Magnetic Bead Growth. The latest market report shows the recombinant protein manufacturing sector is expected to triple in revenue by 2030, with Bio‑Rad listed among the key players. A separate analysis projects the magnetic bead market to grow from $3.3 billion in 2025 to $7.4 billion by 2032, again naming Bio‑Rad as a leader. These developments highlight the company’s expanding role in both protein production and diagnostic reagent markets.